Drug Discov Ther. 2011;5(1):2-11. (DOI: 10.5582/ddt.2011.v5.1.2)

c-Met: A potential therapeutic target for hepatocellular carcinoma.

Gao JJ, Inagaki Y, Xue X, Qu XJ, Tang W


The approval of receptor tyrosine kinase (RTK) targeted agent sorafenib as the first effective drug for the systemic treatment of advanced hepatocellular carcinoma (HCC) represents a milestone in the treatment of this disease. A better understanding of HCC pathogenesis will lead to development of novel targeted treatments. As a typical member of the RTK family, c-Met represents an intriguing target for cancer therapy. The c-Met signaling pathway has been shown to be deregulated and to correlate with poor prognosis in a number of major human cancers. This review discusses the possibility of c-Met as a target in HCC treatment from the following respects: i) c-Met expression and activation profile in HCC, ii) relationship between c-Met and clinicopathologic state and prognosis of HCC, iii) role of c-Met signaling activity in HCC genesis and progression, and iv) strategy of c-Met pathway targeting therapy in HCC treatment.

KEYWORDS: Receptor tyrosine kinases, cancer therapy, clinicopathological features, prognosis, hepatocellular carcinoma

Full Text: